CD4 and non-small cell lung carcinoma: Moreover, Inomata et al. also reported that high numbers of CD4+ PD1+ T cells and CD62Llow CD4+ T cells in the peripheral blood were could predict longer response to PD-1 blockade in NSCLC patients [16, 17].